CLAIMS

1. Use of an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating cancer in an individual, and use of an effective amount of a PD-1 pathway antagonist in the manufacture of a second medicament for treating cancer in the individual, wherein the first medicament and the second medicament are to be administered to the individual.

2. The use according to claim 1, wherein said PD-1 pathway antagonist is an antagonist of PD-1 or an antagonist of a ligand of PD-1.

3. The use according to claim 1 or 2, wherein said PD-1 pathway antagonist is an antibody.

4. The use according to claim 3, wherein said antibody is a monoclonal antibody.

5. The use according to claim 3 or 4, wherein said antibody is a humanized antibody or fully human antibody.

6. The use according to any one of claims 3-5, wherein said antibody is an immunoglobulin G (IgG) antibody.

7. The use according to claim 6, wherein said IgG antibody is an IgG4 antibody.

8. The use according to claim 2, wherein said PD-1 pathway antagonist is selected from the group consisting of AMP-224, BMS-936559, MEDI4736, MPDL3280A, nivolumab, AMP-514, pembrolizumab (MK-3475), and pidilizumab (CT-011).

9. The use according to any one of claims 1-8, wherein said antagonist is an antagonist of PD-1.

10. The use according to claim 9, wherein said antagonist of PD-1 is an anti-PD-1 antibody.

11. The use according to claim 10, wherein said anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), or pidilizumab (CT-011).

12. The use of claim 11 , wherein the anti-PD-1 antibody is nivolumab.

13. The use of any one of claims 1-8, wherein said PD-1 pathway antagonist is an antagonist of PD-L1.

14. The use of claim 13, wherein said antagonist of PD-L1 is an anti-PD-L1 antibody.

15. The use of any one of claims 1-8, wherein said PD-1 pathway antagonist is an antagonist of PD-L2.

16. The use of claim 15, wherein said antagonist of PD-L2 is an anti-PD-L2 antibody.

17. The use according to any one of claims 1-16, wherein a chemotherapeutic agent is to be further administered to said individual.

18. The use according to claim 17, wherein said chemotherapeutic agent is a platinum-based agent.

19. The use according to claim 18, wherein said platinum-based agent is carboplatin.

20. The use according to claim 17, wherein said chemotherapeutic agent is a nucleoside analog.

21. The use according to claim 20, wherein said nucleoside analog is gemcitabine.

22. The use according to any one of claims 1-21, wherein said cancer is breast cancer.

23. The use according to claim 22, wherein said breast cancer is negative for estrogen receptor (ER), progesterone receptor (PR), or HER2.

24. The use according to claim 22 or 23, wherein said breast cancer is a Her2(-) breast cancer.

25. The use according to any one of claims 22-24, wherein said breast cancer is a metastatic breast cancer.

26. The use according to any one of claims 22-25, wherein said breast cancer is a recurrent breast cancer.

27. The use according to any one of claims 1-21, wherein said cancer is a pancreatic cancer.

28. The use according to any one of claims 1-21, wherein said cancer is a lung cancer.

29. The use according to claim 28, wherein said lung cancer is a non-small cell lung cancer (NSCLC).

30. The use according to claim 29, wherein said NSCLC is a stage III or stage IV NSCLC.

31. The use according to claim 29, wherein said NSCLC is a stage IIIB NSCLC.

32. The use according to any one of claims 1-31, wherein said first medicament and said second medicament are to be administered simultaneously or sequentially.

33. The use according to any one of claims 17-31, wherein said first medicament, said second medicament, and said chemotherapeutic agent are to be administered simultaneously or sequentially.

34. The use according to any one of claims 1-33, wherein said nanoparticles in said composition have an average diameter of less than or equal to 200 nm.

35. The use according to any one of claims 1-34, wherein said albumin and said paclitaxel in said composition comprising nanoparticles have a weight ratio from 1:1 to 18:1.

36. The use according to any one of claims 1-34, wherein said albumin and said paclitaxel in said composition comprising nanoparticles have a weight ratio from 1:1 to 9:1.

37. The use of any one of claims 1-34, wherein said albumin and said paclitaxel in said composition comprising nanoparticles have a weight ratio of 9:1.

38. The use according to any one of claims 1-37, wherein said individual is a human.

39. The use according to any of claims 1-38, wherein the first medicament and the second medicament are to be administered via intravenous administration.

40. A kit comprising: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, and b) an effective amount of a PD-1 pathway antagonist.

41. A pharmaceutical composition comprising: a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, and b) an effective amount of a PD-1 pathway antagonist.

42. The kit of claim 40 or the pharmaceutical composition of claim 41, wherein said antagonist is an anti-PD-1 antibody.

43. The kit or pharmaceutical composition of claim 42, wherein said anti-PD-1 antibody is nivolumab.

44. Use of an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating HER2 negative metastatic breast cancer in a human, and use of an effective amount of an anti-PD-1 antibody in the manufacture of a second medicament for treating HER2 negative metastatic breast cancer in a human, wherein the first medicament comprising the effective amount of the composition comprising nanoparticles and the second medicament comprising the effective amount of the anti-PD-1 antibody are to be administered to the human; wherein the effective amount of the composition comprising nanoparticles is from 50 mg/m^2 to 350 mg/m^2; and wherein said first medicament and said second medicament are to be administered via intravenous administration.

45. The use of claim 44, wherein the effective amount of the composition comprising nanoparticles is 75 mg/m^2, 100 mg/m^2, 125 mg/m^2, 150 mg/m^2, 200 mg/m^2, 225 mg/m^2, 250 mg/m^2, or 260 mg/m^2.

46. The use of claim 44, wherein the effective amount of the composition comprising nanoparticles is 100 mg/m^2.

47. The use of any one of claims 44-46, wherein the anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), or pidilizumab (CT-011).

48. The use of claim 47, wherein the anti-PD-1 antibody is nivolumab.

49. The use of any one of claims 44-48, wherein the effective amount of the anti-PD-1 antibody is from 0.1 mg/kg to 10 mg/kg.

50. The use of any one of claims 44-48, wherein the effective amount of the anti-PD-1 antibody is of 5 mg/kg or 3 mg/kg.

51. The use of any one of claims 44-50, wherein said individual is negative for estrogen receptor (ER) and/or progesterone receptor (PR).

52. The use of any one of claims 44-51, wherein said breast cancer is a metastatic breast cancer.

53. The use of any one of claims 44-52, wherein said breast cancer is a recurrent breast cancer.

54. The use of any one of claims 44-53, wherein the first medicament is to be administered on days 1, 8, and 15 of a 28-day cycle and wherein the second medicament is to be administered on days 1 and 15 of a 28-day cycle.

55. Use of an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating pancreatic cancer in a human, and use of an effective amount of an effective amount of an anti-PD-1 antibody in the manufacture of a second medicament for treating pancreatic cancer in a human, wherein the first medicament comprising the effective amount of the composition comprising nanoparticles and the second medicament comprising the effective amount of the anti-PD-1 antibody are to be administered to the human; and wherein the effective amount of the composition comprising nanoparticles is from 50 mg/m^2 to 350 mg/m^2; and wherein said first medicament and said second medicament are to be administered via intravenous administration.

56. The use of claim 55, wherein the effective amount of the composition comprising nanoparticles is 75 mg/m^2, 100 mg/m^2, 125 mg/m^2, 150 mg/m^2, 200 mg/m^2, 225 mg/m^2, or 250 mg/m^2.

57. The use of claim 55, wherein the effective amount of the composition comprising nanoparticles is 125 mg/m^2.

58. The use of any one of claims 55-57, wherein the anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), or pidilizumab (CT-011).

59. The use of claim 58, wherein said anti-PD-1 antibody is nivolumab.

60. The use of any one of claims 55-59, wherein the effective amount of the anti-PD-1 antibody is from 0.1 mg/kg to 10 mg/kg.

61. The use of any one of claims 55-59, wherein the effective amount of the anti-PD-1 antibody is 3 mg/kg.

62. The use of any one of claims 55-61, wherein gemcitabine is to be further administered to the individual.

63. The use of any one of claims 55-62, wherein the first medicament is to be administered on days 1, 8, and 15 of a 28-day cycle and wherein the second medicament is to be administered on days 1 and 15 of a 28-day cycle.

64. Use of an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin in the manufacture of a first medicament for treating non-small cell lung cancer (NSCLC) in a human, use of an effective amount of carboplatin in the manufacture of a second medicament for treating non-small cell lung cancer (NSCLC) in a human, and use of an effective amount of an anti-PD-1 antibody in the manufacture of a third medicament for treating non-small cell lung cancer (NSCLC) in a human, wherein the first medicament comprising the effective amount of the composition comprising nanoparticles, the second medicament comprising the effective amount of the carboplatin, and the third medicament comprising the effective amount of the anti-PD-1 antibody are to be administered to the human; wherein the effective amount of the composition comprising nanoparticles is from 50 mg/m^2 to 350 mg/m^2; and wherein said first medicament, said second medicament, and said third medicament are to be administered via intravenous administration.

65. The use of claim 64, wherein the effective amount of the composition comprising nanoparticles is 75 mg/m^2, 100 mg/m^2, 125 mg/m^2, 150 mg/m^2, 200 mg/m^2, 225 mg/m^2, or 250 mg/m^2.

66. The use of claim 64, wherein the effective amount of the composition comprising nanoparticles is 100 mg/m^2.

67. The use of any one of claims 64-66, wherein the anti-PD-1 antibody is nivolumab, AMP 514, pembrolizumab (MK-3475), or pidilizumab (CT-011).

68. The use of claim 67, wherein the anti-PD-1 antibody is nivolumab.

69. The use of any one of claims 64-68, wherein the effective amount of the anti-PD-1 antibody is from 0.1 mg/kg to 10 mg/kg.

70. The use of any one of claims 64-68, wherein the effective amount of the anti-PD-1 antibody is 5 mg/kg.

71. The use of any one of claims 64-68, wherein the effective amount of the anti-PD-1 antibody is 3 mg/kg.

72. The use of claim any one of claims 64-71, wherein the first medicament is to be administered on days 1, 8, and/or 15 of a 21-day cycle; wherein the second medicament is to be administered on day 1 of a 21 day cycle; and wherein the third medicament is to be administered on day 15 of a 21-day cycle.

73. The use according to any one of claims 64-72, wherein said NSCLC is a stage III or stage IV NSCLC.

74. The use according to any one of claims 64-72, wherein said NSCLC is a stage IIIB NSCLC.